Cargando…

Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies

Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery and penetration into tissues. Cytoreductive surg...

Descripción completa

Detalles Bibliográficos
Autores principales: Harper, Megan M., Kim, Joseph, Pandalai, Prakash K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143396/
https://www.ncbi.nlm.nih.gov/pubmed/35628966
http://dx.doi.org/10.3390/jcm11102840
_version_ 1784715796194263040
author Harper, Megan M.
Kim, Joseph
Pandalai, Prakash K.
author_facet Harper, Megan M.
Kim, Joseph
Pandalai, Prakash K.
author_sort Harper, Megan M.
collection PubMed
description Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery and penetration into tissues. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are surgical interventions that directly target peritoneal tumors and have improved outcomes for PC resulting from appendiceal and colorectal cancer (CRC). Despite these radical therapies, long-term survival remains infrequent, and recurrence is common. The reasons for these outcomes are multifactorial and signal the need for the continued development of novel therapeutics, techniques, and approaches to improve outcomes for these patients. Here, we review landmark historical studies that serve as the foundation for current recommendations, recent discoveries, clinical trials, active research, and areas of future interest in CRS/HIPEC to treat PC originating from appendiceal and colorectal malignancies.
format Online
Article
Text
id pubmed-9143396
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91433962022-05-29 Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies Harper, Megan M. Kim, Joseph Pandalai, Prakash K. J Clin Med Review Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery and penetration into tissues. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are surgical interventions that directly target peritoneal tumors and have improved outcomes for PC resulting from appendiceal and colorectal cancer (CRC). Despite these radical therapies, long-term survival remains infrequent, and recurrence is common. The reasons for these outcomes are multifactorial and signal the need for the continued development of novel therapeutics, techniques, and approaches to improve outcomes for these patients. Here, we review landmark historical studies that serve as the foundation for current recommendations, recent discoveries, clinical trials, active research, and areas of future interest in CRS/HIPEC to treat PC originating from appendiceal and colorectal malignancies. MDPI 2022-05-18 /pmc/articles/PMC9143396/ /pubmed/35628966 http://dx.doi.org/10.3390/jcm11102840 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Harper, Megan M.
Kim, Joseph
Pandalai, Prakash K.
Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies
title Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies
title_full Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies
title_fullStr Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies
title_full_unstemmed Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies
title_short Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies
title_sort current trends in cytoreductive surgery (crs) and hyperthermic intraperitoneal chemotherapy (hipec) for peritoneal disease from appendiceal and colorectal malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143396/
https://www.ncbi.nlm.nih.gov/pubmed/35628966
http://dx.doi.org/10.3390/jcm11102840
work_keys_str_mv AT harpermeganm currenttrendsincytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecforperitonealdiseasefromappendicealandcolorectalmalignancies
AT kimjoseph currenttrendsincytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecforperitonealdiseasefromappendicealandcolorectalmalignancies
AT pandalaiprakashk currenttrendsincytoreductivesurgerycrsandhyperthermicintraperitonealchemotherapyhipecforperitonealdiseasefromappendicealandcolorectalmalignancies